The impact of generic reference pricing interventions in the statin market

Health Policy

Volumn 84, Issue 1, 2007, Pages 14-29

  Puig Junoy, Jaume ^a  

^a DEPARTMENT OF ECONOMICS AND BUSINESS   (Spain)

Author keywords

Drug costs; Generic drugs; Pharmaceutical economics

Indexed keywords

ATORVASTATIN; CARDYL; CERIVASTATIN; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPEMOL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG MARKETING; PROSPECTIVE PRICING; TIME SERIES ANALYSIS;

COMMERCE; COST SAVINGS; DRUGS, GENERIC; ECONOMICS, PHARMACEUTICAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NATIONAL HEALTH PROGRAMS; REIMBURSEMENT MECHANISMS; SPAIN;

EID: 34848861325     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2007.02.010     Document Type: Article

References (17)

1. OECD. Health Data File 2004. Paris: 2005.
2. López-Casasnovas G., and Puig-Junoy J. Review of the literature on reference pricing. Health Policy 54 (2000) 87-123
3. Aaserud M., Dahlgren A.T., Kösters J.P., Oxman A.D., Ramsay C., and Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. The Cochrane Database of Systematic Reviews (2006) [Issue 2]
4. Dickson M., and Redwood H. Pharmaceutical reference prices. How do they work in practice?. PharmacoEconomics 14 5 (1998) 471-479
5. Ioannides-Demos L.L., Ibrahim J.E., and McNeil J.J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. PharmacoEconomics 20 9 (2002) 577-591
6. McLaughin P. Reference-based pricing of prescription drugs. The Canadian Journal of Cardiology 13 1 (1997) 31-32
7. Puig-Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67 (2004) 149-165
8. Ministerio de Sanidad y Consumo (MSC). Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 2004. Información Terapéutica del Sistema Nacional de Salud 29 2 (2005) 49-52
9. Wright J.M. Are the benefits of statins a class effect?. Canadian Medical Association Journal 172 9 (2005) 1194-1195
10. Grundy S.M., et al. Implications of recent trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
11. Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?. RAND Journal of Economics 33 3 (2002) 469-487
12. Puig-Junoy J. What is required to evaluate the impact of pharmaceutical reference pricing?. Applied Health Economics and Health Policy 4 2 (2005) 87-98
13. Wagner A.K., Soumerai S.B., and Zhang F. Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapy 27 (2002) 299-309
14. Kanavos P., et al. Measuring, monitoring and evaluating policy outcomes in the pharmaceutical sector. In: Mossialos E., Mrazek M., and Walley T. (Eds). Regulating pharmaceuticals in Europe. striving for efficiency, equity and quality (2004), Open University Press, London [Chapter 5]
15. Wooldridge J.M. Introductory econometrics. a modern approach (2003), Thomson South-Western, Mason
16. Aronsson T., Bergman M.A., and Rudholm N. The impact of generic drug competition on brand name market shares-evidence from micro data. Review of Industrial Organization 19 (2001) 425-435
17. Zweifel P., and Crivelli L. Price regulation of drugs: lessons from Germany. Journal of Regulatory Economics 10 (1996) 257-273